Evidence map›Paper›PMID 25666149›Full record

ArticleAntimicrobial agents and chemotherapy2015

Trafficking through the late endosome significantly impacts Candida albicans tolerance of the azole antifungals.

Arturo Luna-Tapia, Morgan E Kerns, Karen E Eberle, Branko S Jursic, Glen E Palmer

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Ergosterol from Yeasts PromotesInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Screening theAntimicrobial agents and chemotherapy · 2019
    Article
  11. Article
  12. Article
  13. The Vacuolar CamSphere · 2019
    Article
  14. Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-ResistantFrontiers in cellular and infection microbiology · 2019
    Article
  15. Loss of C-5 Sterol Desaturase Activity inAntimicrobial agents and chemotherapy · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Arturo Luna-TapiaDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana, USA.
Morgan E KernsDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana, USA.
Karen E EberleDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana, USA.
Branko S JursicDepartment of Chemistry, University of New Orleans, New Orleans, Louisiana, USA.
Glen E PalmerDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana, USA gpalmer5@uthsc.edu.
Louisiana State University Health Sciences Center New Orleans · USUniversity of New Orleans · US

Funding

Molecular and chemical validation of the vacuole as a new antifungal targetR01AI099080 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PALMER, GLEN · 2014 to 2018
$1.9M
A New Class of Broad Spectrum Antifungal AgentsR21AI097664 · NIAID · LSU HEALTH SCIENCES CENTER · PI PALMER, GLEN · 2012 to 2013
$391k
NIAID NIH HHS R01 AI099080NIAID NIH HHS R01AI099080NIAID NIH HHS R21 AI097664NIAID NIH HHS R21AI097664
6 · The paper itself

Abstract

The azole antifungals block ergosterol biosynthesis by inhibiting lanosterol demethylase (Erg11p). The resulting depletion of cellular ergosterol and the accumulation of "toxic" sterol intermediates are both thought to compromise plasma membrane function. However, the effects of ergosterol depletion upon the function of intracellular membranes and organelles are not well described. The purpose of this study was to characterize the effects of azole treatment upon the integrity of the Candida albicans vacuole and to determine whether, in turn, vacuolar trafficking influences azole susceptibility. Profound fragmentation of the C. albicans vacuole can be observed as an early consequence of azole treatment, and it precedes significant growth inhibition. In addition, a C. albicans vps21Δ/Δ mutant, blocked in membrane trafficking through the late endosomal prevacuolar compartment (PVC), is able to grow significantly more than the wild type in the presence of several azole antifungals under standard susceptibility testing conditions. Furthermore, the vps21Δ/Δ mutant is able to grow despite the depletion of cellular ergosterol. This phenotype resembles an exaggerated form of "trailing growth" that has been described for some clinical isolates. In contrast, the vps21Δ/Δ mutant is hypersensitive to drugs that block alternate steps in ergosterol biosynthesis. On the basis of these results, we propose that endosomal trafficking defects may lead to the cellular "redistribution" of the sterol intermediates that accumulate following inhibition of ergosterol biosynthesis. Furthermore, the destination of these intermediates, or the precise cellular compartments in which they accumulate, may be an important determinant of their toxicity and thus ultimately antifungal efficacy.

Indexed as

Antifungal AgentsAzolesCandida albicansDrug Resistance, FungalEndosomesErgosterolMicrobial Sensitivity TestsPlasmidsVacuolesAntifungal AgentsAzolesErgosterol

Identifiers

PMID25666149
PMCPMC4356793
OpenAlexW2009729619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.